LAssa Fever Adjunct Treatment With DEXamethasone
ConditionLassa Fever
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorBernhard Nocht Institute for Tropical Medicine
About this trial
Dexamethasone is a corticosteroid which can modulate inflammatory-mediated tissue damage associated with a wide range of infectious diseases. Dexamethasone is routinely used for treatment of tuberculous meningitis and for pneumococcal meningitis in adults. In Coronavirus Disease 2019 (COVID-19) dexamethasone is also effectively preventing immune mediated damage of the lungs. There is also indication that dexamethasone may be promising in severe LF.
Eligibility criteria
Qualifiers
Age ≥ 18 years
LF confirmed by RT-PCR (reverse-transcription polymerase chain reaction) with a cycle threshold (Ct) value < 30
Alert, confusion, voice, pain, unresponsive (ACVPU) other than A
Systolic blood pressure < 90 mmHg
Disqualifiers
Pregnancy (evidenced by positive urine pregnancy test in women of child-bearing potential)
Lactation following live birth
Known intolerance and contra-indications to ribavirin or dexamethasone
Patients who already received a corticosteroid within the preceding 7 days
Trial design
Treatments tested in this trial
- Dexamethasone
- Ribavirin
Treatment groups
42 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov